Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications in Older Patients
NCT07576543Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dexmedetomidine, esketamine in Postoperative neurocognitive disorder (PND), sponsored by Peking University First Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
dexmedetomidineesketamine
03
Conditions
Postoperative neurocognitive disorder (PND)
Beyond the preview
Go deeper on NCT07576543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07576543.